GAIA

𝐌𝐢𝐥𝐞𝐬𝐭𝐨𝐧𝐞𝐬 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐰𝐨𝐫𝐥𝐝'𝐬 𝐟𝐢𝐫𝐬𝐭 𝐚𝐧𝐝 𝐨𝐧𝐥𝐲 𝐟𝐮𝐥𝐥𝐲 𝐚𝐮𝐭𝐨𝐦𝐚𝐭𝐞𝐝 𝐝𝐢𝐠𝐢𝐭𝐚𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐟𝐨𝐫 𝐁𝐏𝐃! We're thrilled to announce significant milestones for priovi, our digital therapeutic for the management of Borderline Personality Disorder (BPD): Its effectiveness has now been impressively confirmed in a large clinical trial (RCT) with 580 patients and priovi has become GAIA's fifth DTx (DiGA) to gain permanent status by the German Federal Institute for Drugs and Medical Devices (BfArM). priovi is distinguished as the pioneering and the only fully automated digital therapeutic specifically tailored for BPD. Its efficacy is substantiated by a rigorous randomized controlled trial (RCT) with 580 participants. Results revealed that individuals using priovi reported a substantial 61.3% decrease in suicide attempts compared to the control group, alongside notable improvements in BPD symptoms. The success of priovi not only highlights the capabilities of GAIA, but also reinforces Germany as a leader for digital health research and innovation. We are excited about the future and remain committed to furthering advancements in digital health. Join us in celebrating this achievement and the potential it signifies for the field of psychiatry, pharmaceutical sciences and, most importantly, for the 80 million global patients suffering from BPD. More information: https://lnkd.in/epDThZYd

Wir schätzen die konstruktive Diskussion zu diesem wichtigen Thema sehr. Innovation braucht die richtigen Rahmenbedingungen, damit wir gemeinsam die Zukunft der Gesundheitsversorgung gestalten können.

🎉 We are thrilled to announce that reclarit, our cognitive behavioural digital health application for rheumatoid arthritis patients, has won the prestigious EULAR 2024 Abstract Award in the HPR category! 🏆 This award recognizes our study on reclarit, led by PD Dr. Gitta Jacob as the principal author. Special thanks to the EULAR 2024 Abstract Award Committee for this honor and for the opportunity to present our work at the EULAR 2024 European Congress of Rheumatology in Vienna. Frank Behrens MD graciously accepted the award on our behalf and presented the results during the oral presentation. In celebration of this achievement, we are delighted to donate the €1,000 prize money: ✨ €500 to the German Rheumatism Foundation ✨ €500 to the German Children’s Rheumatism Foundation We believe in giving back and supporting the important work these organizations do. Stay tuned for more updates and thank you for your continued support! #DigitalHealth #RheumatoidArthritis #EULAR2024 #Award #HealthTech #MentalHealth

𝗔𝗜-𝗣𝗼𝘄𝗲𝗿𝗲𝗱 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲: 𝗗𝗿. 𝗠𝗮𝗿𝗶𝗼 𝗪𝗲𝗶𝘀𝘀 𝗼𝗻 𝗚𝗔𝗜𝗔'𝘀 𝟮𝟱 𝗬𝗲𝗮𝗿𝘀 𝗼𝗳 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺𝘀: Advanced AI platforms, like GAIA's broca, deliver personalized therapies to patients 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗢𝘂𝘁𝗰𝗼𝗺𝗲𝘀: AI-powered digital therapeutics improve patient compliance and outcomes 𝗣𝗵𝘆𝘀𝗶𝗰𝗶𝗮𝗻 𝗦𝘂𝗽𝗽𝗼𝗿𝘁: AI assists physicians in critical aspects of patient care 𝗖𝗼𝘀𝘁 𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆: AI-driven digital therapeutics reduce healthcare costs 𝗝𝗼𝗶𝗻 𝗨𝘀 𝗶𝗻 𝗦𝗵𝗮𝗽𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲:  GAIA is actively seeking partnerships to market our existing products globally, co-develop new therapeutic solutions, and enhance drug compliance. Together, we can redefine healthcare, making it a more holistic and empowering experience. 📖 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗶𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄 𝗵𝗲𝗿𝗲: https://lnkd.in/edCD-eqR #DigitalHealth #DTx #AIinHealthcare #DigitalTherapeutics #Innovation #HealthcareTransformation #GAIA

Pharma als #Schlüsselindustrie schafft die Basis für wirtschaftliche Unabhängigkeit und Versorgungssicherheit. Unsere Innovationskraft ist elementar, wenn es um die technologische Souveränität Deutschlands geht. ❗️ Aber technologische Souveränität ist kein Selbstläufer. Dafür müssen dringend die richtigen Rahmenbedingungen geschaffen werden! 👉 Warum? In den sechs wichtigen Technologiefeldern Gen-/Zelltherapien, RNA-Technologie, Biologika, Small Molecules, Impfstoffe und digitale Therapeutika ist Deutschlands Souveränität nicht gesichert. Das geht aus einer Studie des Fraunhofer Institute for Systems and Innovation Research ISI hervor. Demnach könnten wachsende Abhängigkeiten Deutschlands in Forschung und Entwicklung und in der Produktion von Arzneimitteln zu erheblichen Schwierigkeiten des Wirtschaftsstandorts führen – mit schmerzhaften Konsequenzen bei der Versorgungssicherheit. 📢 Was es braucht, um Deutschland zukunftsfest zu machen: https://lnkd.in/eURj3Njw #ForschungistDeutschlandsbesteMedizin #Pharma #Schlüsselindustrie #StarkamStandort

**𝐔𝐒 𝐆𝐨𝐯𝐞𝐫𝐧𝐦𝐞𝐧𝐭 𝐫𝐞𝐜𝐨𝐠𝐧𝐢𝐳𝐞𝐬 𝐆𝐀𝐈𝐀’𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐀𝐬𝐬𝐞𝐭𝐬 𝐰𝐢𝐭𝐡 𝐭𝐡𝐞 𝐥𝐚𝐮𝐧𝐜𝐡 𝐨𝐟 𝐭𝐡𝐞 𝐂𝐀𝐅𝐄 𝐌𝐒 𝐓𝐫𝐢𝐚𝐥** We are thrilled to announce that the CAFE MS Trial (Clinical Advances in Fatigue and Exercise for Multiple Sclerosis) has officially launched in the US, marking another significant milestone for GAIA’s innovative treatment assets. We are incredibly proud and thankful for being part of this research project, alongside top-of-class research organisations, tremendously committed patient organisations and of course the VA, who not only generously funded this trial but will also be a comprehensive supporter for bringing this treatment option to the ones who so deliberately suffer. Please find the official press release here: https://lnkd.in/enTuFUTA #evidencedbasedmedicine #dtx #veteransadministration #livingwithms

𝐆𝐀𝐈𝐀 𝐢𝐬 𝐫𝐞𝐭𝐮𝐫𝐧𝐢𝐧𝐠 𝐭𝐨 𝐁𝐈𝐎 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 2024 𝐢𝐧 𝐒𝐚𝐧 𝐃𝐢𝐞𝐠𝐨! As global R&D leaders in real #digitaltherapeutics with an almost 25-year history in bringing true breakthrough innovations to various healthcare systems, we see an ever-increasing demand in scalable, evidence-based therapeutics - either complementing/enhancing drug treatments or targeting unmet medical needs directly. We are therefore looking forward to returning to this premier event on the West Coast, discussing the commercial and strategic opportunities that come along with real, fully-automated digital therapeutics as portfolio expansions for pharma and medtech in many markets around the world. Please connect with us through the #BIO2024 partnering platform or DM our chief of staff Giorgio Papitto directly to secure your meeting with members of GAIA’s senior leadership team, including our CCO Stan Sugarman and our CMSO Dr. Matthias Zenker, MD. Together, we can explore strategic partnerships and unlock the scientific and commercial potential of cutting-edge #DigitalTherapeutics for the pharma and medtech sectors. #BIO2024 #SanDiego #Innovation #DTx #MedTech #DigitalHealth

Möchten Sie aktiv an der Erforschung und Weiterentwicklung von 𝐤𝐥𝐚𝐫𝐢𝐯𝐚 teilnehmen? Wir suchen aktuell interessierte Betroffene für unsere klinische Studie, die die Wirksamkeit von 𝐤𝐥𝐚𝐫𝐢𝐯𝐚 prüft. Ihre Teilnahme könnte dazu beitragen, das Leben von Menschen mit Psoriasis zu verbessern. Erfahren Sie mehr über die Teilnahme an unserer Studie auf unserer Webseite: https://klariva-studie.de/ #GAIA #DTx #digitalhealth #psoriasis #klariva #Studienteilnehmer

We are thrilled to announce that GAIA's innovative digital therapeutic (DTx) asset, klariva, is being featured in an article on The Pharma Letter! klariva addresses the needs of patients with psoriasis, and we are confident that it has the potential to be a transformative solution for these patients. The article highlights klariva's unique benefits, including: 𝐄𝐦𝐩𝐨𝐰𝐞𝐫𝐦𝐞𝐧𝐭: klariva equips patients with the tools and resources needed to actively manage their condition. 𝐀𝐜𝐜𝐞𝐬𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐲: klariva breaks down barriers to care by providing anonymous and remote access to support, eliminating the stigma and logistical hurdles often associated with traditional therapy. 𝐇𝐨𝐥𝐢𝐬𝐭𝐢𝐜 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡: klariva tackles psoriasis not just as a physical condition, but also addresses the mental and emotional aspects that significantly impact patients' well-being. We're passionate about developing evidence-based and accessible DTx solutions that empower individuals to improve their health. We're thrilled about the potential of klariva to make a positive impact on the lives of psoriasis patients worldwide. Read the full article here: https://lnkd.in/edJgdqjB #DTx #psoriasis #digitalhealth #GAIA #klariva

At GAIA, we believe in the transformative potential of real Digital Therapeutics in revolutionizing healthcare around the world. Grounded in empirical evidence and scientific rigor, we leverage over 26 years of R&D expertise to pioneer cutting-edge products that yield tangible results across indications. Curious about the scientific and commercial frontiers of our AI-based, fully-automated therapies? Connect with us at BIO-Europe Spring 2024 in Barcelona from March 18th to 20th. Our leadership team will be on hand to showcase our innovative solutions, latest scientific results as well as their commercial potential for the pharma and medtech industry. To schedule a meeting for exploring potential collaborations, feel free to reach out to Giorgio Papitto or connect with us on the partneringONE platform https://lnkd.in/ejmgNpNu. Let's shape the future of healthcare together. #bioeurope2024 #healthcareinnovation #digitalhealth #aipoweredhealthcare #DTx